gw844520 has been researched along with Malaria--Falciparum* in 2 studies
2 other study(ies) available for gw844520 and Malaria--Falciparum
Article | Year |
---|---|
Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
Malaria is still considered as the major parasitic disease and the development of artemisinin resistance does not improve this alarming situation. Based on the recent identification of relevant malaria targets in the artemisinin resistance context, novel drug combinations were evaluated against artemisinin-sensitive and artemisinin-resistant Plasmodium falciparum parasites. Corresponding hybrid molecules were also synthesized and evaluated for comparison with combinations and individual pharmacophores (e.g. atovaquone, mefloquine or triclosan). Combinations and hybrids showed remarkable antimalarial activity (IC Topics: Antimalarials; Artemisinins; Atovaquone; Dose-Response Relationship, Drug; Drug Resistance; Humans; Malaria, Falciparum; Mefloquine; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Structure-Activity Relationship; Triclosan | 2021 |
Quinolone-3-diarylethers: a new class of antimalarial drug.
The goal for developing new antimalarial drugs is to find a molecule that can target multiple stages of the parasite's life cycle, thus impacting prevention, treatment, and transmission of the disease. The 4(1H)-quinolone-3-diarylethers are selective potent inhibitors of the parasite's mitochondrial cytochrome bc1 complex. These compounds are highly active against the human malaria parasites Plasmodium falciparum and Plasmodium vivax. They target both the liver and blood stages of the parasite as well as the forms that are crucial for disease transmission, that is, the gametocytes, the zygote, the ookinete, and the oocyst. Selected as a preclinical candidate, ELQ-300 has good oral bioavailability at efficacious doses in mice, is metabolically stable, and is highly active in blocking transmission in rodent models of malaria. Given its predicted low dose in patients and its predicted long half-life, ELQ-300 has potential as a new drug for the treatment, prevention, and, ultimately, eradication of human malaria. Topics: Animals; Antimalarials; Atovaquone; Drug Resistance; Drug Synergism; Life Cycle Stages; Malaria; Malaria, Falciparum; Mice; Plasmodium falciparum; Plasmodium vivax; Proguanil; Pyridones; Quinolones | 2013 |